|
1
|
Tripathi CK, Banga J and Mishra V:
Microbial heparin/Heparan Sulphate lyases: Potential and
applications. Appl Microbiol Biotechno. 94:307–321. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ma Q, Dudas B, Hejna M, Cornelli U, Lee
JM, Lorens S, Mervis R, Hanin I and Fareed J: The blood-brain
barrier accessibility of a heparin-derived oligosaccharides C3.
Thromb Res. 105:447–453. 2002.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Belmiro CL, Souza HS, Elia CC,
Castelo-Branco MT, Silva FR, Machado RL and Pavão MS: Biochemical
and immunohistochemical analysis of glycosaminoglycans in inflamed
and non-inflamed intestinal mucosa of patients with Crohn's
disease. Int J Colorectal Dis. 20:295–304. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tracey KJ, Fong Y, Hesse DG, Manogue KR,
Lee AT, Kuo GC, Lowry SF and Cerami A: Anti-cachectin/TNF
monoclonal antibodies prevent septic shock during lethal
bacteraemia. Nature. 330:662–664. 1987.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Chen S, He Y, Hu Z, Lu S, Yin X, Ma X, Lv
C and Jin G: Heparanase mediates intestinal inflammation and injury
in a mouse model of sepsis. J Histochem Cytochem. 65:241–249.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fu L, Zhang F, Li G, Onishi A, Bhaskar U,
Sun P and Linhardt RJ: Structure and activity of a new
low-molecular-weight heparin produced by enzymatic ultrafiltration.
J Pharm Sci. 103:1375–1383. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Weiss RJ, Esko JD and Tor Y: Targeting
heparin and heparan sulfate protein interactions. Org Biomol Chem.
15:5656–5668. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kandrotas RJ: Heparin pharmacokinetics and
pharmacodynamics. Clin Pharmacokinet. 22:359–374. 1992.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Castelli R, Porro F and Tarsia P: The
heparins and cancer: Review of clinical trials and biological
properties. Vasc Med. 9:205–213. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Casu B, Guerrini M and Torri G: Structural
and conformational aspects of the anticoagulant and anti-thrombotic
activity of heparin and dermatan sulfate. Curr Pharm Des.
10:939–949. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pike RN, Buckle AM, le Bonniec BF and
Church FC: Control of the coagulation system by serpins. Getting by
with a little help from glycosaminoglycans. FEBS J. 272:4842–4851.
2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Walenga JM and Lyman GH: Evolution of
heparin anticoagulants to ultra-low-molecular-weight heparins: A
review of pharmacologic and clinical differences and applications
in patients with cancer. Crit Rev Oncol Hematol. 88:1–18.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li X, Liu Z, Luo M, Xi Y, Li C, Wang S and
Yang R: Therapeutic effect of low-molecular-weight heparin on adult
sepsis: A meta-analysis. Ann Palliat Med.Mar. 10:3115–3127.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Vlodavsky I, Friedmann Y, Elkin M, Aingorn
H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal
I, et al: Mammalian heparanase: Gene cloning, expression and
function in tumor progression and metastasis. Nat Med. 5:793–802.
1999.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
McKenzie E, Tyson K, Stamps A, Smith P,
Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, et
al: Cloning and expression profiling of Hpa2, a novel mammalian
heparanase family member. Biochem Biophys Res Commun.
276:1170–1177. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yingying X, Yong Z, Zhenning W, Xue Z, Li
J, Yang L and Huimian X: Role of heparanase-1 in gastric carcinoma
invasion. Asian Pac J Cancer Prev. 10:151–154. 2009.PubMed/NCBI
|
|
18
|
Meirovitz A, Hermano E, Lerner I, Zcharia
E, Pisano C, Peretz T and Elkin M: Role of heparanase in
radiation-enhanced invasiveness of pancreatic carcinoma. Cancer
Res. 71:2772–2780. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shafat I, Pode D, Peretz T, Ilan N,
Vlodavsky I and Nisman B: Clinical significance of urine heparanase
in bladder cancer progression. Neoplasia. 10:125–130.
2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Boyango I, Barash U, Naroditsky I, Li JP,
Hammond E, Ilan N and Vlodavsky I: Heparanase cooperates with Ras
to drive breast and skin tumorigenesis. Cancer Res. 74:4504–4514.
2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lerner I, Hermano E, Zcharia E, Rodkin D,
Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R,
Sherman Y, et al: Heparanase powers a chronic inflammatory circuit
that promotes colitis-associated tumorigenesis in mice. J Clin
Invest. 121:1709–1721. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Akbarshahi H, Axelsson JB, Said K,
Malmström A, Fischer H and Andersson R: TLR4 dependent heparan
sulphate-induced pancreatic inflammatory response is IRF3-mediated.
J Transl Med. 9(219)2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fernandes CL, Escouto GB and Verli H:
Structural glycobiology of heparinase II from Pedobacter heparinus.
J Biomol Struct Dyn. 32:1092–1102. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Häcker U, Nybakken K and Perrimon N:
Heparan sulphate proteoglycans: The sweet side of development. Nat
Rev Mol Cell Biol. 6:530–541. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Fux L, Ilan N, Sanderson RD and Vlodavsky
I: Heparanase: Busy at the cell surface. Trends Biochem Sci.
34:511–519. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rivara S, Milazzo FM and Giannini G:
Heparanase: A rainbow pharmacological target associated to multiple
pathologies including rare diseases. Future Med Chem. 8:647–680.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Levy-Adam F, Feld S, Suss-Toby E,
Vlodavsky I and Ilan N: Heparanase facilitates cell adhesion and
spreading by clustering of cell surface heparan sulfate
proteoglycans. PLoS One. 3(e2319)2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bass MD, Roach KA, Morgan MR,
Mostafavi-Pour Z, Schoen T, Muramatsu T, Mayer U, Ballestrem C,
Spatz JP and Humphries MJ: Syndecan-4-dependent Rac1 regulation
determines directional migration in response to the extracellular
matrix. J Cell Biol. 177:527–538. 2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dovas A, Yoneda A and Couchman JR:
PKCbeta-dependent activation of RhoA by syndecan-4 during focal
adhesion formation. J Cell Sci. 119:2837–2846. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tkachenko E, Elfenbein A, Tirziu D and
Simons M: Syndecan-4 clustering induces cell migration in a
PDZ-dependent manner. Circ Res. 98:1398–1404. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang X, Han X, Xia K, Xu Y, Yang Y,
Oshima K, Haeger SM, Perez MJ, McMurtry SA, Hippensteel JA, et al:
Circulating heparin oligosaccharides rapidly target the hippocampus
in sepsis, potentially impacting cognitive functions. Proc Natl
Acad Sci USA. 116:9208–9213. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ruan J, Trotter TN, Nan L, Luo R, Javed A,
Sanderson RD, Suva LJ and Yang Y: Heparanase inhibits
osteoblastogenesis and shifts bone marrow progenitor cell fate in
myeloma bone disease. Bone. 57:10–17. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Smith PN, Freeman C, Yu D, Chen M, Gatenby
PA, Parish CR and Li RW: Heparanase in primary human osteoblasts. J
Orthop Res. 28:1315–1322. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Thompson CA, Purushothaman A, Ramani VC,
Vlodavsky I and Sanderson RD: Heparanase regulates secretion,
composition, and function of tumor cell-derived exosomes. J Biol
Chem. 288:10093–10099. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shteingauz A, Boyango I, Naroditsky I,
Hammond E, Gruber M, Doweck I, Ilan N and Vlodavsky I: Heparanase
enhances tumor growth and chemoresistance by promoting autophagy.
Cancer Res. 75:3946–3957. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Dunlop EA and Tee AR: mTOR and autophagy:
A dynamic relationship governed by nutrients and energy. Semin Cell
Dev Biol. 36:121–129. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Qiu P, Liu Y and Zhang J: Review: The role
and mechanisms of macrophage autophagy in sepsis. Inflammation.
42:6–19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vlodavsky I, Eldor A, Haimovitz-Friedman
A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR and
Fuks Z: Expression of heparanase by platelets and circulating cells
of the immune system: Possible involvement in diapedesis and
extravasation. Invasion Metastasis. 12:112–127. 1992.PubMed/NCBI
|
|
39
|
Young E: The anti-inflammatory effects of
heparin and related compounds. Thromb Res. 122:743–752.
2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ilan N, Elkin M and Vlodavsky I:
Regulation, function and clinical significance of heparanase in
cancer metastasis and angiogenesis. Int J Biochem Cell Biol.
38:2018–2039. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Li JP and Vlodavsky I: Heparin, heparan
sulfate and heparanase in inflammatory reactions. Thromb Haemost.
102:823–828. 2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Flynn S and Eisenstein S: Inflammatory
bowel disease presentation and diagnosis. Surg Clin North Am.
99:1051–1062. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Dias AM, Correia A, Pereira MS, Almeida
CR, Alves I, Pinto V, Catarino TA, Mendes N, Leander M, Oliva-Teles
MT, et al: Metabolic control of T cell immune response through
glycans in inflammatory bowel disease. Proc Natl Acad Sci USA.
115:E4651–E4660. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Clayburgh DR, Shen L and Turner JR: A
porous defense: The leaky epithelial barrier in intestinal disease.
Lab Invest. 84:282–291. 2004.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bode L, Salvestrini C, Park PW, Li JP,
Esko JD, Yamaguchi Y, Murch S and Freeze HH: Heparan sulfate and
syndecan-1 are essential in maintaining murine and human intestinal
epithelial barrier function. J Clin Invest. 118:229–238.
2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Bischoff SC, Barbara G, Buurman W,
Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A and Wells JM:
Intestinal permeability-a new target for disease prevention and
therapy. BMC Gastroenterol. 14(189)2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Baud V and Karin M: Signal transduction by
tumor necrosis factor and its relatives. Trends Cell Biol.
11:372–377. 2001.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pender SL, Braegger C, Gunther U,
Monteleone G, Meuli M, Schuppan D and Macdonald TT: Matrix
metalloproteinases in necrotising enterocolitis. Pediatr Res.
54:160–164. 2003.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hermano E, Lerner I and Elkin M:
Heparanase enzyme in chronic inflammatory bowel disease and colon
cancer. Cell Mol Life Sci. 69:2501–2513. 2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Chiba T, Marusawa H and Ushijima T:
Inflammation-associated cancer development in digestive organs:
Mechanisms and roles for genetic and epigenetic modulation.
Gastroenterology. 143:550–563. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gupta RB, Harpaz N, Itzkowitz S, Hossain
S, Matula S, Kornbluth A, Bodian C and Ullman T: Histologic
inflammation is a risk factor for progression to colorectal
neoplasia in ulcerative colitis: A cohort study. Gastroenterology.
133:1099–1105. 2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Vlodavsky I, Ilan N, Nadir Y, Brenner B,
Katz BZ, Naggi A, Torri G, Casu B and Sasisekharan R: Heparanase,
heparin and the coagulation system in cancer progression. Thromb
Res. 120 (Suppl 2):S112–S120. 2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zheng L, Jiang G, Mei H, Pu J, Dong J, Hou
X and Tong Q: Small RNA interference-mediated gene silencing of
heparanase abolishes the invasion, metastasis and angiogenesis of
gastric cancer cells. BMC Cancer. 10(33)2010.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Levy MM, Fink MP, Marshall JC, Abraham E,
Angus D, Cook D, Cohen J, Opal SM, Vincent JL and Ramsay G:
SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International
sepsis definitions conference. Crit Care Med. 31:1250–1256.
2003.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Shankar-Hari M, Phillips GS, Levy ML,
Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD and
Singer M: Sepsis Definitions Task Force. Developing a new
definition and assessing new clinical criteria for septic shock:
For the third international consensus definitions for sepsis and
septic shock (Sepsis-3). JAMA. 315:775–787. 2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Vincent JL, Jones G, David S, Olariu E and
Cadwell KK: Frequency and mortality of septic shock in Europe and
North America: A systematic review and meta-analysis. Crit Care.
23(196)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Bermejo-Martin JF, Martín-Fernandez M,
López-Mestanza C, Duque P and Almansa R: Shared features of
endothelial dysfunction between sepsis and its preceding risk
factors (Aging and Chronic Disease). J Clin Med.
7(400)2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Martin-Fernandez M, Vaquero-Roncero LM,
Almansa R, Gómez-Sánchez E, Martín S, Tamayo E, Esteban-Velasco MC,
Ruiz-Granado P, Aragón M, Calvo D, et al: Endothelial dysfunction
is an early indicator of sepsis and neutrophil degranulation of
septic shock in surgical patients. BJS Open. 4:524–534.
2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Floer M, Götte M, Wild MK, Heidemann J,
Gassar ES, Domschke W, Kiesel L, Luegering A and Kucharzik T:
Enoxaparin improves the course of dextran sodium sulfate-induced
colitis in syndecan-1-deficient mice. Am J Pathol. 176:146–157.
2009.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Yan Y, Ji Y, Su N, Mei X, Wang Y, Du S,
Zhu W, Zhang C, Lu Y and Xing XH: Non-anticoagulant effects of low
molecular weight heparins in inflammatory disorders: A review.
Carbohydr Polym. 160:71–81. 2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sallisalmi M, Tenhunen J, Yang R, Oksala N
and Pettilä V: Vascular adhesion protein-1 and syndecan-1 in septic
shock. Acta Anaesthesiol Scand. 56:316–322. 2012.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Nelson A, Berkestedt I, Schmidtchen A,
Ljunggren L and Bodelsson M: Increased levels of glycosaminoglycans
during septic shock: Relation to mortality and the antibacterial
actions of plasma. Shock. 30:623–627. 2008.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Weinbaum S, Tarbell JM and Damiano ER: The
structure and function of the endothelial glycocalyx layer. Annu
Rev Biomed Eng. 9:121–167. 2007.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Yini S, Heng Z, Xin A and Xiaochun M:
Effect of unfractionated heparin on endothelial glycocalyx in a
septic shock model. Acta Anaesthesiol Scand. 59:160–169.
2015.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Schmidt EP, Yang Y, Janssen WJ, Gandjeva
A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX,
et al: The pulmonary endothelial glycocalyx regulates neutrophil
adhesion and lung injury during experimental sepsis. Nat Med.
18:1217–1223. 2012.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Obritsch MD, Fish DN, MacLaren R and Jung
R: Nosocomial infections due to multidrug-resistant Pseudomonas
aeruginosa: Epidemiology and treatment options.
Pharmacotherapy. 25:1353–1364. 2005.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Dzvova N, Colmer-Hamood JA, Griswold JA
and Hamood AN: Heparinase is essential for Pseudomonas
aeruginosa virulence during thermal injury and infection.
Infect Immun. 86:e00755–e00817. 2017.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Dzvova N, Colmer-Hamood JA, Griswold JA
and Hamood AN: Isolation and characterization of HepP: A
virulence-related Pseudomonas aeruginosa heparinase. BMC Microbiol.
17(233)2017.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Martin L, De Santis R, Koczera P, Simons
N, Haase H, Heinbockel L, Brandenburg K, Marx G and Schuerholz T:
The synthetic antimicrobial peptide 19-2.5 interacts with
heparanase and heparan sulfate in murine and human sepsis. PLoS
One. 10(e0143583)2015.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Zarychanski R, Abou-Setta AM, Kanji S,
Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL, McIntyre L,
Fox-Robichaud AE, et al: The efficacy and safety of heparin in
patients with sepsis: A systematic review and metaanalysis. Crit
Care Med. 43:511–518. 2015.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Cho SX, Berger PJ, Nold-Petry CA and Nold
MF: The immunological landscape in necrotising enterocolitis.
Expert Rev Mol Med. 18(e12)2016.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Reintam Blaser A, Malbrain ML, Starkopf J,
Fruhwald S, Jakob SM, De Waele J, Braun JP, Poeze M and Spies C:
Gastrointestinal function in intensive care patients: Terminology,
definitions and management. Recommendations of the ESICM Working
Group on Abdominal Problems. Intensive Care Med. 38:384–394.
2012.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Chen H, Zhang H, Li W, Wu S and Wang W:
Acute gastrointestinal injury in the intensive care unit: A
retrospective study. Ther Clin Risk Manag. 11:1523–1529.
2015.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Hu B, Sun R, Wu A, Ni Y, Liu J, Guo F,
Ying L, Ge G, Ding A, Shi Y, et al: Severity of acute
gastrointestinal injury grade is a predictor of all-cause mortality
in critically ill patients: A multicenter, prospective,
observational study. Crit Care. 21(188)2017.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Reintam A, Parm P, Kitus R, Starkopf J and
Kern H: Gastrointestinal failure score in critically ill patients:
A prospective observational study. Crit Care.
12(R90)2008.PubMed/NCBI View
Article : Google Scholar
|
|
77
|
Fleischmann C, Scherag A, Adhikari NK,
Hartog CS, Tsaganos T, Schlattmann P, Angus DC and Reinhart K:
International Forum of Acute Care Trialists. Assessment of global
incidence and mortality of hospital-treated sepsis. Current
estimates and limitations. Am J Respir Crit Care Med. 193:259–272.
2016.PubMed/NCBI View Article : Google Scholar
|
